Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer

被引:25
|
作者
Bian, Xiaoqian [2 ]
Du, Siyao [2 ]
Yue, Zhibin [3 ]
Gao, Si [2 ]
Zhao, Ruimeng [2 ]
Huang, Guoliang [2 ]
Guo, Liangcun [2 ]
Peng, Can [2 ]
Zhang, Lina [1 ,2 ]
机构
[1] China Med Univ, Dept Radiol, Affiliated Hosp 1, Nanjing North St 155, Shenyang 110001, Liaoning, Peoples R China
[2] China Med Univ, Dept Radiol, Affiliated Hosp 1, Shenyang, Peoples R China
[3] China Med Univ, Sch Intelligent Med, Shenyang, Peoples R China
基金
中国国家自然科学基金;
关键词
breast cancer; radiomics; T1-weighted contrast enhanced; apparent diffusion coefficient; HER2-low; NOMOGRAM;
D O I
10.1002/jmri.28628
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Multiparametric MRI radiomics could distinguish human epidermal growth factor receptor 2 (HER2)-positive from HER2-negative breast cancers. However, its value for further distinguishing HER2-low from HER2-negative breast cancers has not been investigated.Purpose: To investigate whether multiparametric MRI-based radiomics can distinguish HER2-positive from HER2-negative breast cancers (task 1) and HER2-low from HER2-negative breast cancers (task 2).Study Type: Retrospective.Population: Task 1: 310 operable breast cancer patients from center 1 (97 HER2-positive and 213 HER2-negative); task 2: 213 HER2-negative patients (108 HER2-low and 105 HER2-zero); 59 patients from center 2 (16 HER2-positive, 27 HER2-low and 16 HER2-zero) for external validation.Field Strength/Sequence: A 3.0 T/T1-weighted contrast-enhanced imaging (T1CE), diffusion-weighted imaging (DWI)-derived apparent diffusion coefficient (ADC).Assessment: Patients in center 1 were assigned to a training and internal validation cohort at a 2:1 ratio. Intratumoral and peritumoral features were extracted from T1CE and ADC. After dimensionality reduction, the radiomics signatures (RS) of two tasks were developed using features from T1CE (RS-T1CE), ADC (RS-ADC) alone and T1CE + ADC combination (RS-Com).Statistical Tests: Mann-Whitney U tests, the least absolute shrinkage and selection operator, receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).Results: For task 1, RS-ADC yielded higher area under the ROC curve (AUC) in the training, internal, and external validation of 0.767/0.725/0.746 than RS-T1CE (AUC = 0.733/0.674/0.641). For task 2, RS-T1CE yielded higher AUC of 0.765/0.755/0.678 than RS-ADC (AUC = 0.706/0.608/0.630). For both of task 1 and task 2, RS-Com achieved the best performance with AUC of 0.793/0.778/0.760 and 0.820/0.776/0.711, respectively, and obtained higher clinical benefit in DCA compared with RS-T1CE and RS-ADC. The calibration curves of all RS demonstrated a good fitness.Data Conclusion: Multiparametric MRI radiomics could noninvasively and robustly distinguish HER2-positive from HER2-negative breast cancers and further distinguish HER2-low from HER2-negative breast cancers.Evidence Level: 3.Technical Efficacy: Stage 2.
引用
收藏
页码:1603 / 1614
页数:12
相关论文
共 50 条
  • [11] Human epidermal growth factor receptor 2 testing in breast cancer
    Nielsen, Kirsten Vang
    Jorgensen, Jan T.
    Schonau, Andreas
    Oster, Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 4020 - 4020
  • [12] Human epidermal growth factor receptor 2 testing in breast cancer
    Nielsen, Kirsten Vang
    Jorgensen, Jan T.
    Schonau, Andreas
    Oster, Anne
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2007, 131 (09) : 1330 - 1330
  • [13] Role of epidermal growth factor receptor in breast cancer
    Masuda, Hiroko
    Zhang, Dongwei
    Bartholomeusz, Chandra
    Doihara, Hiroyoshi
    Hortobagyi, Gabriel N.
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) : 331 - 345
  • [14] The role of the epidermal growth factor receptor in breast cancer
    Chan, Samuel K.
    Hill, Mark E.
    Gullick, William J.
    JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2006, 11 (01) : 3 - 11
  • [15] The Role of the Epidermal Growth Factor Receptor in Breast Cancer
    Samuel K. Chan
    Mark E. Hill
    William J. Gullick
    Journal of Mammary Gland Biology and Neoplasia, 2006, 11 : 3 - 11
  • [16] Role of epidermal growth factor receptor in breast cancer
    Hiroko Masuda
    Dongwei Zhang
    Chandra Bartholomeusz
    Hiroyoshi Doihara
    Gabriel N. Hortobagyi
    Naoto T. Ueno
    Breast Cancer Research and Treatment, 2012, 136 : 331 - 345
  • [17] Mind the target: human epidermal growth factor receptor 2 in colorectal cancer
    Saude-Conde, Rita
    Rasschaert, Gertjan
    Bregni, Giacomo
    Hendlisz, Alain
    Sclafani, Francesco
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (04) : 382 - 388
  • [18] Epidermal Growth Factor Receptor Target in Breast Cancer Treatment
    Zhao, Ruya
    Kaakati, Rayan N.
    Hallenbeck, Scott T.
    Li, Chuan-yuan
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 227 (04) : E80 - E80
  • [19] Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer
    Curigliano, G.
    Dent, R.
    Earle, H.
    Modi, S.
    Tarantino, P.
    Viale, G.
    Tolaney, S. M.
    ESMO OPEN, 2024, 9 (04)
  • [20] Progesterone receptor and human epidermal growth factor receptor 2 status: An independent influence on the efficacy of endocrine therapy in breast cancer?
    Ponzone, R
    Maggiorotto, F
    Robba, C
    Fuso, L
    Sismondi, P
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1481 - 1482